Life Sciences INDUSTRIES

We represent industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges in all aspects of the life sciences industry.

Recognized both globally and nationally as a leading life sciences practice, WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for more than four decades. From biotechnology, pharmaceutical and medical device companies at all stages of growth to venture capitalists and investment banks, we understand the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces. Our work in supporting life sciences clients has led to the group being named a "Practice Group of the Year" by Law360.

Many of our lawyers have advanced degrees in relevant scientific disciplines and more than 100 of our lawyers devote a significant portion of their practice to aspects critical to life sciences clients. Those aspects include corporate finance, licensing and alliances, mergers and acquisitions, patent prosecution and other intellectual property matters, patent and product liability. We also work with clients on securities, litigation and FDA, competition and other regulatory matters.


Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)


Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)


We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, licensing agreements and collaborations. We also have protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

 Read about some of our recent life sciences transactions.


Our life sciences clients include:

  • Achillion
  • Agios Pharmaceuticals
  • Argos Therapeutics
  • AVEO Pharmaceuticals
  • Bristol-Myers Squibb
  • Cephalon
  • Cerulean Pharma
  • CoNCERT Pharmaceuticals
  • Cynosure
  • Curis
  • Durata Therapeutics
  • Eleven Biotherapeutics
  • Emergent BioSolutions
  • Epizyme
  • Idenix
  • Idera Pharmaceuticals
  • Infinity Pharmaceuticals
  • Karyopharm Therapeutics
  • The Medicines Company
  • Medtronic
  • Merrimack Pharmaceuticals
  • Novartis Pharmaceuticals Corporation
  • Ophthotech Corporation
  • PerkinElmer
  • PTC Therapeutics
  • Tetraphase Pharmaceuticals
  • Thermo Fisher Scientific
  • uniQure biopharma

Publications & News


February 3, 2016

WilmerHale Reps Editas Medicine in $94.4 Million IPO

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016.

January 12, 2016

WilmerHale Named Among Top Three Life Sciences Law Firms

WilmerHale has been named among the top three Best Life Sciences Law Firms for 2016 in the inaugural Life Science Index.

December 10, 2015

Overview of Securities Law Provisions of the FAST Act

On December 4, 2015, President Obama signed into law the Fixing America’s Surface Transportation Act. The FAST Act, which is aimed principally at authorizing spending on highway and transit projects, includes several amendments to the Jumpstart Our Business Startups Act (JOBS Act) and other securities law provisions, some of which are effective immediately.

December 10, 2015

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

October 29, 2015

Park Square, EY and WilmerHale Release 16th Annual Tech and Life Sciences Compensation and Entrepreneurship Study

According to an executive compensation study of private businesses released today, non-founder C-suite executives at life sciences and healthcare companies saw their cash compensation increase by 3.3 percent year-over-year, while comparable executives at private technology firms experienced an average increase of 3.5 percent.

September 14, 2015

LMG Life Sciences Release 2015 Rankings, Again Names WilmerHale a "Life Cycle Firm"

In its latest edition, LMG Life Sciences recognizes eight WilmerHale practice areas and 16 attorneys, and for the fourth consecutive year names WilmerHale a "Life Cycle Firm."

August 17, 2015

WilmerHale Lawyers Named Among the 2016 Best Lawyers in America®, Seven Recognized as Lawyers of the Year

Best Lawyers in America® recognizes 99 WilmerHale lawyers and names seven partners as Lawyers of the Year in its 22nd edition. Only one lawyer in each legal practice specialty within each region is honored as a Lawyer of the Year.

July 14, 2015

WilmerHale Welcomes Intellectual Property Partner James Hill to Los Angeles Office

James Hill, who earned his MD from the University of Southern California's Keck School of Medicine, joins the firm in the Intellectual Property Department and will also be a member of the IP Litigation and Life Sciences Practices.

July 6, 2015

Managing IP Recognizes WilmerHale, Attorneys in 2015 IP Stars Handbook

Managing Intellectual Property has released the third annual edition of its IP Stars Handbook—a guide that identifies the leading IP firms and lawyers in the United States—prominently ranking WilmerHale and 18 of its partners.

July 1, 2015

WilmerHale Named a Leading National Firm in the United States by The Legal 500

The Legal 500 United States has released its annual rankings, selecting WilmerHale as one of the preeminent law firms in the country.


As a result of our skill and experience in the life sciences field, we have received many accolades, including:

  • Chambers USA: America's Leading Lawyers for Business 2007-2015 named WilmerHale a top law firm for life sciences with attorneys who are "consistently excellent people," "very responsive" and who "continue to stand out." WilmerHale is "a very strong firm" who is "in the top 1%" in the area of life sciences. 
  • Chambers Global 2013, 2014 and 2015 recognized WilmerHale as a leader in life sciences with an "outstanding US practice coupled with international reach."
  • Chambers Europe 2013, 2014 and 2015 recognized WilmerHale as a leader in life sciences in Germany.
  • Lake Whillians - Named among the top three Best Life Sciences Law Firms for 2016 in the inaugural Life Science Index, and selected as the top firm in the patent category.
  • Law360  has named WilmerHale as a "Life Sciences Practice Group of the Year" for 2013 in its annual competition which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year. This is the fourth consecutive year the firm has been named a "Practice Group of the Year" by Law360.
  • Legal 500 US 2013, 2014 and 2015 ranked WilmerHale among the top law firms for life sciences. The guidebook says our firm "brings a great deal of experience to any situation" and says that our firm "has access to additional expertise/resources to help solve any problem."
  • LMG Life Sciences ranked the firm in their 2012-2015 editions in the areas of patent prosecution, corporate, and licensing and collaboration. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms within the life sciences industry.
  • LMG Life Sciences named WilmerHale the winner of the 2013 "Canadian Impact Deals of the Year" award. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP recognized WilmerHale in 2013, 2014 and 2015 as one of the best in the nation for life sciences and in 2013 named the firm the "National Patent Contentious Firm of the Year" and "Pharmaceutical IP Litigation Firm of the Year."
  • PLC Life Sciences Industry Super League 2012 named WilmerHale among the top ten law firms for having "a strong transatlantic life sciences practice."
  • PLC Cross-border Life Sciences Handbook 2011/12, 2009/10, 2008/09, 2007/08 and 2006/07 named WilmerHale a leading law firm in the area of life sciences.
  • The American Lawyer placed WilmerHale on their 2015 "A-List" as one of the nation's leading law firms. This is the 12th year the firm has received this recognition.
  • The American Lawyer recognized WilmerHale as its 2014 "IP Litigation Department of the Year." This is the second time that WilmerHale has been named a winner and the third time the firm has been named a finalist in this contest since the first year the title was awarded to a firm in 2004.
  • The National Law Journal named WilmerHale to the 2012 and 2013 Intellectual Property Hot Lists, which honors firms who demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® recognized the firm in their 2014 and 2015 "Best Law Firms" lists in the first-tier nationally in biotechnology law, corporate law, intellectual property litigation, patent law, securities, technology law and venture capital law. WilmerHale also received first-tier metropolitan rankings in Boston and New York for biotechnology law and corporate law; and in Boston, San Francisco and Washington DC for intellectual property litigation.